Abstract is: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited genetic disorder that predisposes those affected to potentially life-threatening abnormal heart rhythms or arrhythmias. The arrhythmias seen in CPVT typically occur during exercise or at times of emotional stress, and classically take the form of bidirectional ventricular tachycardia or ventricular fibrillation. Those affected may be asymptomatic, but they may also experience blackouts or even sudden cardiac death. CPVT is caused by genetic mutations affecting proteins that regulate the concentrations of calcium within cardiac muscle cells. The most commonly identified gene is RYR2, which encodes a protein included in an ion channel known as the ryanodine receptor; this channel releases calcium from a cell's internal calcium store, the sarcoplasmic reticulum, during every heartbeat. CPVT is often diagnosed from an ECG recorded during an exercise tolerance test, but it may also be diagnosed with a genetic test. The condition is treated with medication including beta-adrenoceptor blockers or flecainide, or with surgical procedures including sympathetic denervation and implantation of a defibrillator. It is thought to affect as many as one in ten thousand people and is estimated to cause 15% of all unexplained sudden cardiac deaths in young people. The condition was first defined in 1978, and the underlying genetics were described in 2001.
| rare disease | Q929833 |
| class of disease | Q112193867 |
| monogenic disease | Q1225194 |
| heart conduction disease | Q1361515 |
| genetic cardiac rhythm disease | Q55785258 |
| P699 | Disease Ontology ID | DOID:0060674 |
| P557 | DiseasesDB | 33816 |
| P10565 | Encyclopedia of China (Third Edition) ID | 579514 |
| P2888 | exact match | http://identifiers.org/doid/DOID:0060674 |
| http://purl.obolibrary.org/obo/DOID_0060674 | ||
| http://www.orpha.net/ORDO/Orphanet_3286 | ||
| P646 | Freebase ID | /m/0268hwz |
| P4317 | GARD rare disease ID | 4421 |
| P7464 | Genetics Home Reference Conditions ID | catecholaminergic-polymorphic-ventricular-tachycardia |
| P494 | ICD-10 ID | I47.2 |
| P4229 | ICD-10-CM | I47.2 |
| P7807 | ICD-11 ID (Foundation) | 976309888 |
| P7329 | ICD-11 ID (MMS) | BC65.5 |
| P493 | ICD-9 ID | 427 |
| P665 | KEGG ID | H01019 |
| P6366 | Microsoft Academic ID | 2778178275 |
| P492 | OMIM ID | 604772 |
| 604772 | ||
| P10283 | OpenAlex ID | C2778178275 |
| P1550 | Orphanet ID | 3286 |
| P4233 | PatientsLikeMe condition ID | catecholaminergic-polymorphic-ventricular-tachycardia |
| P5806 | SNOMED CT ID | 419671004 |
| P2892 | UMLS CUI | C5574922 |
| P11143 | WikiProjectMed ID | Catecholaminergic polymorphic ventricular tachycardia |
| P2293 | genetic association | RYR2 | Q18031341 |
| P1995 | health specialty | cardiology | Q10379 |
| P5008 | on focus list of Wikimedia project | WikiProject Medicine | Q4099686 |
| P780 | symptoms and signs | ventricular tachycardia | Q56002 |
| Q28024494 | catecholaminergic polymorphic ventricular tachycardia 1 |
| Q28024495 | catecholaminergic polymorphic ventricular tachycardia 2 |
| Q28024496 | catecholaminergic polymorphic ventricular tachycardia 3 |
| Q28024497 | catecholaminergic polymorphic ventricular tachycardia 4 |
| Q28024498 | catecholaminergic polymorphic ventricular tachycardia 5 |
| Q92142202 | 50 Years of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - Time to Explore the Dark Side of the Moon |
| Q92025664 | A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone |
| Q53227880 | A Clinical Case of Catecholaminergic Polymorphic Ventricular Tachycardia: The Clinical Suspicious and the Need of Genetics. |
| Q128290581 | A DEADLY CASE OF THE JITTERS: CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA AND THE ROLE OF LEFT CARDIAC SYMPATHETIC DENERVATION |
| Q61800544 | A Homozygous Mutation in a Japanese Patient with Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q91112339 | A Novel Calsequestrin 2 Deletion Causing Catecholaminergic Polymorphic Ventricular Tachycardia and Sudden Cardiac Death |
| Q46548721 | A Novel mutation of F189L in CASQ2 in families with catecholaminergic polymorphic ventricular tachycardia |
| Q33156517 | A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations |
| Q128065198 | A case of catecholaminergic polymorphic ventricular tachycardia diagnosed as having long QT syndrome 25 years ago |
| Q97535701 | A case of catecholaminergic polymorphic ventricular tachycardia masquerading as an intractable seizure |
| Q33157554 | A case of catecholaminergic polymorphic ventricular tachycardia. |
| Q43284915 | A case with catecholaminergic polymorphic ventricular tachycardia unmasked after successful ablation of atrial tachycardias from pulmonary veins |
| Q84633394 | A classic electrocardiographic manifestation of catecholaminergic polymorphic ventricular tachycardia |
| Q91801354 | A compound heterozygosity of Tecrl gene confirmed in a catecholaminergic polymorphic ventricular tachycardia family |
| Q33163429 | A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia. |
| Q52580654 | A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. |
| Q47276542 | A focus on pharmacological management of catecholaminergic polymorphic ventricular tachycardia |
| Q37305886 | A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses. |
| Q92620733 | A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia |
| Q86081750 | A new mutation in the ryanodine receptor 2 gene (RYR2 C2277R) as a cause catecholaminergic polymorphic ventricular tachycardia |
| Q51488238 | A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia. |
| Q33164590 | A novel cardiac ryanodine receptor gene (RyR2) mutation in an athlete with aborted sudden cardiac death: a case of adult-onset catecholaminergic polymorphic ventricular tachycardia |
| Q55843608 | A novel early onset lethal form of catecholaminergic polymorphic ventricular tachycardia maps to chromosome 7p14-p22 |
| Q38829197 | A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia |
| Q28238170 | A novel mutation in FKBP12.6 binding region of the human cardiac ryanodine receptor gene (R2401H) in a Japanese patient with catecholaminergic polymorphic ventricular tachycardia |
| Q84301682 | A novel mutation in the RYR2 gene leading to catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation: dose-dependent arrhythmia-event suppression by β-blocker therapy |
| Q33168032 | A novel variant in RyR2 causes familiar catecholaminergic polymorphic ventricular tachycardia. |
| Q90845588 | A novel variant of the CASQ2 gene in a Chinese family with catecholaminergic polymorphic ventricular tachycardia |
| Q64935508 | A rare cause of sudden cardiac arrest: Catecholaminergic polymorphic ventricular tachycardia. |
| Q51874603 | Abnormal propagation of calcium waves and ultrastructural remodeling in recessive catecholaminergic polymorphic ventricular tachycardia. |
| Q78390804 | Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia |
| Q36696236 | Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients. |
| Q37465870 | Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. |
| Q46723257 | Adenosine triphosphate terminates bidirectional ventricular tachycardia in a patient with catecholaminergic polymorphic ventricular tachycardia |
| Q39022381 | Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia |
| Q42699881 | Alternans in genetically modified langendorff-perfused murine hearts modeling catecholaminergic polymorphic ventricular tachycardia |
| Q97641528 | An International Multi-Center Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2- Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q112686665 | An Optogenetic Arrhythmia Model-Insertion of Several Catecholaminergic Polymorphic Ventricular Tachycardia Mutations Into Caenorhabditis elegans UNC-68 Disturbs Calstabin-Mediated Stabilization of the Ryanodine Receptor Homolog |
| Q93181530 | An Update on the Diagnosis and Management of Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q47298913 | An optogenetic arrhythmia model to study catecholaminergic polymorphic ventricular tachycardia mutations |
| Q60492171 | An unusual catecholaminergic polymorphic ventricular tachycardia not inducible at stress test |
| Q49055965 | Anesthesia for a patient with catecholaminergic polymorphic ventricular tachycardia |
| Q35904740 | Anesthesia for videoscopic left cardiac sympathetic denervation in children with congenital long QT syndrome and catecholaminergic polymorphic ventricular tachycardia--a case series |
| Q89902086 | Anesthetic management of a child with catecholaminergic polymorphic ventricular tachycardia undergoing insertion of implantable cardioverter defibrillator : a case report |
| Q55384198 | Antiarrhythmic Effects of Carvedilol and Flecainide in Cardiomyocytes Derived from Catecholaminergic Polymorphic Ventricular Tachycardia Patients. |
| Q28547114 | Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models |
| Q83455336 | Are there juvenile and adult types in patients with catecholaminergic polymorphic ventricular tachycardia? |
| Q33159716 | Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia |
| Q58608511 | Arrhythmia initiation in catecholaminergic polymorphic ventricular tachycardia type 1 depends on both heart rate and sympathetic stimulation |
| Q35279976 | Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function |
| Q79851890 | Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model |
| Q28595062 | Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia |
| Q46981935 | Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia |
| Q35082640 | Atrial arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia--is there a mechanistic link between sarcoplasmic reticulum Ca(2+) leak and re-entry? |
| Q89856015 | Atropine-induced sinus tachycardia protects against exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia |
| Q46094761 | Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? |
| Q86521653 | Beta-blockers in the treatment of catecholaminergic polymorphic ventricular tachycardia |
| Q33161262 | Bidirectional ventricular tachycardia: a hallmark of catecholaminergic polymorphic ventricular tachycardia |
| Q92110606 | Bilateral cardiac sympathetic denervation in catecholaminergic polymorphic ventricular tachycardia |
| Q34586612 | Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry |
| Q50055771 | Bradycardia is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by RYR2 Mutations. |
| Q93092047 | CASQ2 variants in Chinese children with catecholaminergic polymorphic ventricular tachycardia |
| Q39150543 | Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. |
| Q30557177 | CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. |
| Q45273441 | Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations |
| Q33155477 | Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia |
| Q37072276 | Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia. |
| Q88417369 | Calmodulin Mutants Linked to Catecholaminergic Polymorphic Ventricular Tachycardia Fail to Inhibit Human RyR2 Channels |
| Q54644396 | Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia. |
| Q33165145 | Calmodulin mutations causing catecholaminergic polymorphic ventricular tachycardia confer opposing functional and biophysical molecular changes |
| Q28235110 | Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia |
| Q42586012 | Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: a simulation study of cellular mechanism |
| Q28262015 | Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia |
| Q93022735 | Cardiac arrest in a mother and daughter and the identification of a novel RYR2 variant, predisposing to low penetrant catecholaminergic polymorphic ventricular tachycardia in a four-generation Canadian family |
| Q33154615 | Cardiac ryanodine receptor gene (hRyR2) mutation underlying catecholaminergic polymorphic ventricular tachycardia in a Chinese adolescent presenting with sudden cardiac arrest and cardiac syncope |
| Q46037962 | Cardiac sympathetic innervation in a patient with catecholaminergic polymorphic ventricular tachycardia. |
| Q48254346 | Case of undiagnosed catecholaminergic polymorphic ventricular tachycardia presenting with ventricular fibrillation after administration of succinylcholine during anesthesia for modified electroconvulsive therapy. |
| Q28589230 | Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia |
| Q28076072 | Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q55983198 | Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q59701681 | Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q87379298 | Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q88211598 | Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q92624513 | Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q51620369 | Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Associated With Ryanodine Receptor (RyR2) Gene Mutations - Long-Term Prognosis After Initiation of Medical Treatment. |
| Q52333945 | Catecholaminergic Polymorphic Ventricular Tachycardia - Looking to the Future. |
| Q47677618 | Catecholaminergic Polymorphic Ventricular Tachycardia as the Etiology of Emergency Medical Services-Reported Traumatic Arrest |
| Q47580064 | Catecholaminergic Polymorphic Ventricular Tachycardia in Pregnancy |
| Q33166105 | Catecholaminergic Polymorphic Ventricular Tachycardia with QT Prolongation |
| Q51775633 | Catecholaminergic Polymorphic Ventricular Tachycardia. |
| Q33167113 | Catecholaminergic Polymorphic Ventricular Tachycardia: A Rare Cause of Cardiac Arrest Following Blunt Chest Trauma |
| Q88689676 | Catecholaminergic Polymorphic Ventricular Tachycardia: Activity as Tolerated? |
| Q91635720 | Catecholaminergic Polymorphic Ventricular Tachycardia: An Unusual Case of Fright-Induced Prehospital Cardiac Arrest in a Healthy 6-Year-Old Child |
| Q90601496 | Catecholaminergic Polymorphic Ventricular Tachycardia: Challenges During Resuscitation and Post-Cardiac Arrest Care |
| Q64083681 | Catecholaminergic Polymorphic Ventricular Tachycardia: The Cardiac Arrest Where Epinephrine Is Contraindicated |
| Q28287523 | Catecholaminergic polymorphic ventricular tachycardia |
| Q33158333 | Catecholaminergic polymorphic ventricular tachycardia |
| Q82836857 | Catecholaminergic polymorphic ventricular tachycardia |
| Q87396203 | Catecholaminergic polymorphic ventricular tachycardia |
| Q86129816 | Catecholaminergic polymorphic ventricular tachycardia (CPVT) initially diagnosed as idiopathic ventricular fibrillation: the importance of thorough diagnostic work-up and follow-up |
| Q51254048 | Catecholaminergic polymorphic ventricular tachycardia and midventricular Takotsubo cardiomyopathy: a novel association? |
| Q82614767 | Catecholaminergic polymorphic ventricular tachycardia as a cause of sudden death in athletes |
| Q33167603 | Catecholaminergic polymorphic ventricular tachycardia associated with sinus node dysfunction and junctional rhythm: Case report and literature review. |
| Q33156686 | Catecholaminergic polymorphic ventricular tachycardia caused by a novel mutation in the cardiac ryanodine receptor |
| Q33163118 | Catecholaminergic polymorphic ventricular tachycardia detected by an implantable loop recorder in a child |
| Q33151469 | Catecholaminergic polymorphic ventricular tachycardia detected by an insertable loop recorder in a pediatric patient with exercise syncopal episodes |
| Q90447356 | Catecholaminergic polymorphic ventricular tachycardia due to de novo RyR2 mutation: recreational cycling as a trigger of lethal arrhythmias |
| Q33161292 | Catecholaminergic polymorphic ventricular tachycardia found in an adolescent after a methylenedioxymethamphetamine and marijuana-induced cardiac arrest |
| Q33156900 | Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond |
| Q82337846 | Catecholaminergic polymorphic ventricular tachycardia from gene to bedside: state of the art |
| Q44206560 | Catecholaminergic polymorphic ventricular tachycardia in a 3-year-old with occult myocarditis |
| Q46304989 | Catecholaminergic polymorphic ventricular tachycardia in a child with Brugada pattern on ECG: one patient with two diseases? |
| Q33155738 | Catecholaminergic polymorphic ventricular tachycardia in a child: a case report |
| Q33149237 | Catecholaminergic polymorphic ventricular tachycardia in a child: an often unrecognized diagnosis |
| Q33161060 | Catecholaminergic polymorphic ventricular tachycardia in a patient with recurrent exertional syncope |
| Q33158819 | Catecholaminergic polymorphic ventricular tachycardia in adult: a case report |
| Q33173888 | Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients |
| Q33165339 | Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry |
| Q104132882 | Catecholaminergic polymorphic ventricular tachycardia in pregnancy: a case report |
| Q30494293 | Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. |
| Q91202068 | Catecholaminergic polymorphic ventricular tachycardia managed as orthostatic dysregulation and epilepsy in 11- and 15-year-old sisters |
| Q58601770 | Catecholaminergic polymorphic ventricular tachycardia patients with multiple genetic variants in the PACES CPVT Registry |
| Q46961464 | Catecholaminergic polymorphic ventricular tachycardia successfully treated by beta blocker |
| Q33159553 | Catecholaminergic polymorphic ventricular tachycardia with associated sinus node dysfunction. |
| Q48161835 | Catecholaminergic polymorphic ventricular tachycardia, an update. |
| Q33151459 | Catecholaminergic polymorphic ventricular tachycardia, recurrent syncope, and implantable loop recorder |
| Q46654993 | Catecholaminergic polymorphic ventricular tachycardia-related mutations R33Q and L167H alter calcium sensitivity of human cardiac calsequestrin |
| Q33152560 | Catecholaminergic polymorphic ventricular tachycardia. |
| Q31929262 | Catecholaminergic polymorphic ventricular tachycardia. An important diagnosis in children with syncope and normal heart |
| Q37625277 | Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca(2+) regulation |
| Q26747056 | Catecholaminergic polymorphic ventricular tachycardia: An exciting new era |
| Q43073409 | Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. |
| Q33157298 | Catecholaminergic polymorphic ventricular tachycardia: a current overview. |
| Q38793803 | Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy. |
| Q33166391 | Catecholaminergic polymorphic ventricular tachycardia: a rare cause of recurrent syncope |
| Q85393973 | Catecholaminergic polymorphic ventricular tachycardia: disease with different faces |
| Q24674590 | Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death |
| Q38079785 | Catecholaminergic polymorphic ventricular tachycardia: from bench to bedside |
| Q85049086 | Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports |
| Q34557909 | Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights |
| Q28257333 | Catecholaminergic polymorphic ventricular tachycardia: successful emergency treatment with intravenous propranolol |
| Q33165252 | Catecholaminergic polymorphic ventricular tachycardia; possible diagnosis in cases of syncope and sudden death of family members |
| Q28483390 | Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations |
| Q33159040 | Characterization of a novel mutation in the cardiac ryanodine receptor that results in catecholaminergic polymorphic ventricular tachycardia |
| Q91645678 | Characterization of the first induced pluripotent stem cell line generated from a patient with autosomal dominant catecholaminergic polymorphic ventricular tachycardia due to a heterozygous mutation in cardiac calsequestrin-2 |
| Q42081840 | Choking-induced cardiac arrest unmasks a diagnosis of catecholaminergic polymorphic ventricular tachycardia |
| Q92974067 | Chronotropic incompetence as a risk predictor in children and young adults with catecholaminergic polymorphic ventricular tachycardia |
| Q88668514 | Circadian Variation of Ventricular Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q90170780 | Classification and correlation of RYR2 missense variants in individuals with catecholaminergic polymorphic ventricular tachycardia reveals phenotypic relationships |
| Q30251824 | Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia. |
| Q33165777 | Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. |
| Q92896531 | Clinical and genetic investigation of catecholaminergic polymorphic ventricular tachycardia in a consanguineous Tunisian family |
| Q33167249 | Clinical and genetic profile of catecholaminergic polymorphic ventricular tachycardia in Hong Kong Chinese children |
| Q62105551 | Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia |
| Q33147854 | Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. |
| Q33161218 | Clinical characteristics and mutational analysis of the RyR2 gene in seven Czech families with catecholaminergic polymorphic ventricular tachycardia |
| Q128058837 | Clinical characteristics of three Czech families with catecholaminergic polymorphic ventricular tachycardia and pilot results of RyR2 gene mutation analysis |
| Q42949741 | Clinical effectiveness of pulmonary vein isolation for arrhythmic events in a patient with catecholaminergic polymorphic ventricular tachycardia |
| Q33156954 | Clinical experiences of patients with catecholaminergic polymorphic ventricular tachycardia |
| Q24299780 | Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia |
| Q42128337 | Clinical utility gene card for: Catecholaminergic polymorphic ventricular tachycardia (CPVT). |
| Q88668515 | Clockwork and Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q92242630 | Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation |
| Q88689671 | Competitive Sports Participation in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia: A Single Center's Early Experience |
| Q47680651 | Complex atrial arrhythmias as first manifestation of catecholaminergic polymorphic ventricular tachycardia: an unusual course in a patient with a new mutation in ryanodine receptor type 2 gene |
| Q87770893 | Complex diagnosis of catecholaminergic polymorphic ventricular tachycardia |
| Q48230851 | Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia. |
| Q36992757 | Constitutive Intracellular Na+ Excess in Purkinje Cells Promotes Arrhythmogenesis at Lower Levels of Stress Than Ventricular Myocytes From Mice With Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q42410465 | Correction: Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models |
| Q28076784 | Current topics in catecholaminergic polymorphic ventricular tachycardia |
| Q36037969 | Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia |
| Q42859706 | Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model |
| Q33160646 | Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia |
| Q61632866 | Delay to diagnosis amongst patients with catecholaminergic polymorphic ventricular tachycardia |
| Q83170359 | Delayed maximal response to left cardiac sympathectomy for catecholaminergic polymorphic ventricular tachycardia |
| Q33163242 | Dental management of a patient with catecholaminergic polymorphic ventricular tachycardia: a case report. |
| Q57290293 | Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report |
| Q28299768 | Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia |
| Q47663729 | Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia |
| Q89170250 | Differential Diagnosis Between Catecholaminergic Polymorphic Ventricular Tachycardia and Long QT Syndrome Type 1 - Modified Schwartz Score |
| Q79845488 | Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) |
| Q93257610 | Distinct mechanisms mediate pacemaker dysfunction associated with catecholaminergic polymorphic ventricular tachycardia mutations: Insights from computational modeling |
| Q95401374 | Dizziness and syncope in young people: keep your mind open! Case report of the challenging differentiation between arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) and catecholaminergic polymorphic ventricular tachycardia (CPVT) |
| Q33166611 | Early repolarization pattern: a marker of increased risk in patients with catecholaminergic polymorphic ventricular tachycardia |
| Q88668769 | Effects of Catheter Ablation Targeting the Trigger Beats in Inherited Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q58867587 | Effects of Individualized Exercise Training in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 |
| Q33162208 | Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. |
| Q84308532 | Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia |
| Q92921030 | Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload |
| Q38376971 | Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial |
| Q110699016 | Efficacy of RyR2 inhibitor EL20 in induced pluripotent stem cell-derived cardiomyocytes from a patient with catecholaminergic polymorphic ventricular tachycardia |
| Q36594593 | Efficacy of bilateral thoracoscopic sympathectomy in a patient with catecholaminergic polymorphic ventricular tachycardia. |
| Q84960981 | Efficacy of flecainide in a patient with catecholaminergic polymorphic ventricular tachycardia |
| Q38106029 | Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate |
| Q89495906 | Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia |
| Q48012422 | Elimination of Ventricular Arrhythmia in Catecholaminergic Polymorphic Ventricular Tachycardia by Targeting "Catecholamine-Sensitive Area": A Dominant-Subordinate Relationship between Origin Sites of Bidirectional Ventricular Premature Contractions |
| Q91582292 | Exercise testing oversights underlie missed and delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia in young sudden cardiac arrest survivors |
| Q84078790 | Exercise testing: the catecholaminergic polymorphic ventricular tachycardia crystal ball? |
| Q53490873 | Exon 3 deletion of ryanodine receptor causes left ventricular noncompaction, worsening catecholaminergic polymorphic ventricular tachycardia, and sudden cardiac arrest. |
| Q33161522 | Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives |
| Q38633396 | Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RYR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q38032383 | Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia. |
| Q47673840 | Flecainide in CASQ2-mediated catecholaminergic polymorphic ventricular tachycardia: the gift that keeps on giving |
| Q95429683 | Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation |
| Q86550491 | Flecainide monotherapy for catecholaminergic polymorphic ventricular tachycardia: Perspectives and limitations |
| Q59200864 | Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade |
| Q24608179 | Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans |
| Q84064369 | Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia |
| Q34629553 | Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia |
| Q33163165 | Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia |
| Q98946460 | Flipping syncope: The case of an adolescent athlete with syncopal episodes ultimately diagnosed with catecholaminergic polymorphic ventricular tachycardia |
| Q35675536 | Gender Differences in the Inheritance Mode of RYR2 Mutations in Catecholaminergic Polymorphic Ventricular Tachycardia Patients |
| Q92475159 | Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca2+/Calmodulin-Dependent Kinase II |
| Q52714512 | Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. |
| Q45866288 | Gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia |
| Q104468300 | Genealogy and clinical course of catecholaminergic polymorphic ventricular tachycardia caused by the ryanodine receptor type 2 P2328S mutation |
| Q92419896 | Generation of induced pluripotent stem cells (iPSCs) from an infant with catecholaminergic polymorphic ventricular tachycardia carrying the double heterozygous mutations A1855D in RyR2 and Q1362H in SCN10A |
| Q92119024 | Generation of two human induced pluripotent stem cell lines, LUMCi020-A and LUMCi021-A, from two patients with Catecholaminergic Polymorphic Ventricular Tachycardia carrying heterozygous mutations in the RYR2 gene |
| Q33151464 | Genes, exercise and sudden death: molecular basis of familial catecholaminergic polymorphic ventricular tachycardia |
| Q100990161 | Genetic Background of Catecholaminergic Polymorphic Ventricular Tachycardia in Japan |
| Q44293793 | Genetic background of catecholaminergic polymorphic ventricular tachycardia in Japan |
| Q79833033 | Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing |
| Q33160714 | Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q89733420 | Heart Rate Recovery After Exercise Is Associated With Arrhythmic Events in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q30532694 | Heterogeneity of ryanodine receptor dysfunction in a mouse model of catecholaminergic polymorphic ventricular tachycardia |
| Q43182612 | High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening |
| Q90466227 | High-dose flecainide with low-dose β-blocker therapy in catecholaminergic polymorphic ventricular tachycardia: A case report and review of the literature |
| Q27011445 | How to perform and interpret provocative testing for the diagnosis of Brugada syndrome, long-QT syndrome, and catecholaminergic polymorphic ventricular tachycardia |
| Q90919947 | Identification of a novel exon3 deletion of RYR2 in a family with catecholaminergic polymorphic ventricular tachycardia |
| Q90660340 | Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review |
| Q92404510 | Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest |
| Q83821934 | Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia |
| Q57820983 | In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q36667578 | In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia. |
| Q34313368 | In situ confocal imaging in intact heart reveals stress-induced Ca(2+) release variability in a murine catecholaminergic polymorphic ventricular tachycardia model of type 2 ryanodine receptor(R4496C+/-) mutation |
| Q33157356 | Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia |
| Q33551271 | Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia |
| Q114014605 | Increased susceptibility to ventricular arrhythmia at low–normal and moderately low levels of extracellular potassium in catecholaminergic polymorphic ventricular tachycardia |
| Q90377976 | Inefficacious ICD shocks treated with left cardiac sympathetic denervation in a patient with catecholaminergic polymorphic ventricular tachycardia |
| Q51518257 | Inherited catecholaminergic polymorphic ventricular tachycardia due to RYR2 mutation. |
| Q34160930 | Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. |
| Q91929825 | Insights Into the Pathogenesis of Catecholaminergic Polymorphic Ventricular Tachycardia From Engineered Human Heart Tissue |
| Q48105793 | Integration of 60,000 exomes and ACMG guidelines question the role of Catecholaminergic Polymorphic Ventricular Tachycardia-associated variants. |
| Q51061793 | Interpreting Incidentally Identified Variants in Genes Associated With Catecholaminergic Polymorphic Ventricular Tachycardia in a Large Cohort of Clinical Whole-Exome Genetic Test Referrals. |
| Q85005791 | Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia |
| Q60307232 | Investigation of Catecholaminergic Polymorphic Ventricular Tachycardia Children in China: Clinical Characteristics, Delay to Diagnosis, and Misdiagnosis |
| Q28216442 | Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia |
| Q95503814 | Left Cardiac Sympathetic Denervation in Patients with CASQ2-Associated Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q28279395 | Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia |
| Q33161560 | Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome |
| Q51636642 | Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. |
| Q90763897 | Left cardiac sympathetic denervation in the management of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: A meta-regression |
| Q87159192 | Letter by Gow Regarding Article, "Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation" |
| Q87159189 | Letter by Patanè Regarding Article, "Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation" |
| Q88645882 | Letter by Ruiz-Guerrero et al Regarding Article, "Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation" |
| Q91251306 | Linking the heart and the brain: Neurodevelopmental disorders in patients with catecholaminergic polymorphic ventricular tachycardia |
| Q33173930 | Long term course of catecholaminergic polymorphic ventricular tachycardia in children. Apropos of 20 cases with an 8 year-follow-up |
| Q87630294 | Long-QT Syndrome, Brugada Syndrome, and Catecholaminergic Polymorphic Ventricular Tachycardia: A Tale of 3 Diseases |
| Q51572294 | Long-Term Prognosis of Catecholaminergic Polymorphic Ventricular Tachycardia Patients With Ryanodine Receptor (RYR2) Mutations. |
| Q33163179 | Long-term outcomes and factors for predicting ventricular arrhythmia in patients with catecholaminergic polymorphic ventricular tachycardia |
| Q129198625 | MULTIPLE GENETIC VARIANTS IN CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA: A CLINICAL AND MOLECULAR REPORT FROM THE PACES CPVT REGISTRY |
| Q59200863 | Management of Gene-Positive Catecholaminergic Polymorphic Ventricular Tachycardia: Are the Long Term Outcomes on Therapy Really So Poor? |
| Q88754258 | Management of Gene-Positive Catecholaminergic Polymorphic Ventricular Tachycardia: Are the Long Term Outcomes on Therapy Really So Poor? - Reply |
| Q84875153 | Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia |
| Q84842571 | Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy |
| Q33157630 | Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome |
| Q52576349 | Mechanisms of abnormal calcium homeostasis in mutations responsible for catecholaminergic polymorphic ventricular tachycardia. |
| Q33163102 | Modeling Catecholaminergic Polymorphic Ventricular Tachycardia using Induced Pluripotent Stem Cell-derived Cardiomyocytes |
| Q34322985 | Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells |
| Q24306493 | Modulation of human ether a gogo related channels by CASQ2 contributes to etiology of catecholaminergic polymorphic ventricular tachycardia (CPVT) |
| Q99236777 | Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutants |
| Q36853107 | Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia |
| Q89961129 | Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia |
| Q37361927 | Molecular basis of catecholaminergic polymorphic ventricular tachycardia |
| Q80161603 | Molecular diagnostics of catecholaminergic polymorphic ventricular tachycardia using denaturing high-performance liquid chromatography and sequencing |
| Q79833038 | Molecular pathogenesis of catecholaminergic polymorphic ventricular tachycardia: sex matters! |
| Q79906106 | Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves |
| Q35156823 | Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca²⁺release leading to catecholaminergic polymorphic ventricular tachycardia. |
| Q50085974 | Mutation-linked excessively tight interaction between the calmodulin-binding domain and c-terminal domain of the cardiac ryanodine receptor as a novel cause of catecholaminergic polymorphic ventricular tachycardia |
| Q28201561 | Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia |
| Q41268618 | Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia |
| Q33168311 | Nationwide experience of catecholaminergic polymorphic ventricular tachycardia caused by RyR2 mutations |
| Q39395421 | Nebivolol suppresses cardiac ryanodine receptor-mediated spontaneous Ca2+ release and catecholaminergic polymorphic ventricular tachycardia |
| Q30982059 | New Family With Catecholaminergic Polymorphic Ventricular Tachycardia Linked to the Triadin Gene |
| Q50959364 | New data on catecholaminergic polymorphic ventricular tachycardia in Japan: from the bench to the bedside. |
| Q30666264 | New exome data question the pathogenicity of genetic variants previously associated with catecholaminergic polymorphic ventricular tachycardia |
| Q86091957 | Non-ventricular, Clinical, and Functional Features of the RyR2(R420Q) Mutation Causing Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q50579160 | Novel ryanodine receptor 2 mutation associated with a severe phenotype of catecholaminergic polymorphic ventricular tachycardia. |
| Q90339840 | Novel variants in TECRL cause catecholaminergic polymorphic ventricular tachycardia |
| Q113872886 | One family’s clinical odyssey from evolving phenotypic and genotypic knowledge of catecholaminergic polymorphic ventricular tachycardia and long QT syndrome |
| Q33919047 | Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice |
| Q33163389 | Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. |
| Q127003018 | P5025Structural insights into catecholaminergic polymorphic ventricular tachycardia-associated RyR2 mutant channels using a three-dimensional in silico model |
| Q113186283 | PE-568-04 A DISTINCT AND POTENTIALLY MORE SEVERE NEUROCARDIAC PHENOTYPE AMONG PEDIATRIC PATIENTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA |
| Q33161429 | Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia. |
| Q37465444 | Paralogue annotation identifies novel pathogenic variants in patients with Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia. |
| Q52687047 | Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2. |
| Q28067569 | Patient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening In Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q36409821 | Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2. |
| Q36169155 | Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q33168745 | Percutaneous renal sympathetic denervation in catecholaminergic polymorphic ventricular tachycardia |
| Q99729619 | Peripartum management of a patient with catecholaminergic polymorphic ventricular tachycardia |
| Q37396106 | Phospholamban knockout breaks arrhythmogenic Ca²⁺ waves and suppresses catecholaminergic polymorphic ventricular tachycardia in mice |
| Q33166057 | Physical and Psychological Consequences of Left Cardiac Sympathetic Denervation in Long-QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q91207510 | Plakophilin-2 Truncation Variants in Patients Clinically Diagnosed With Catecholaminergic Polymorphic Ventricular Tachycardia and Decedents With Exercise-Associated Autopsy Negative Sudden Unexplained Death in the Young |
| Q84288373 | Possible targets of therapy for catecholaminergic polymorphic ventricular tachycardia. - Insight from a theoretical model - |
| Q50700554 | Post-natal heart adaptation in a knock-in mouse model of calsequestrin 2-linked recessive catecholaminergic polymorphic ventricular tachycardia. |
| Q39163186 | Postexertional supraventricular tachycardia in children with catecholaminergic polymorphic ventricular tachycardia |
| Q35242390 | Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. |
| Q92533570 | Pregnancy in Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q30498471 | Prevention of Ventricular Arrhythmia and Calcium Dysregulation in a Catecholaminergic Polymorphic Ventricular Tachycardia Mouse Model Carrying Calsequestrin-2 Mutation |
| Q97878645 | Protein expression profiles in murine ventricles modeling catecholaminergic polymorphic ventricular tachycardia: effects of genotype and sex |
| Q37396920 | Protein kinase A-dependent biophysical phenotype for V227F-KCNJ2 mutation in catecholaminergic polymorphic ventricular tachycardia |
| Q47644451 | Psychosocial Implications of Living with Catecholaminergic Polymorphic Ventricular Tachycardia in Adulthood |
| Q42701447 | Purkinje cell calcium dysregulation is the cellular mechanism that underlies catecholaminergic polymorphic ventricular tachycardia |
| Q42377056 | Questioning flecainide's mechanism of action in the treatment of catecholaminergic polymorphic ventricular tachycardia |
| Q44292826 | RYR2 and CASQ2 mutations in patients suffering from catecholaminergic polymorphic ventricular tachycardia |
| Q61451117 | Radiofrequency catheter ablation for drug-refractory atrial tachyarrhythmias in a patient with catecholaminergic polymorphic ventricular tachycardia: A case report |
| Q99634561 | Rare RYR2 p.Thr85Ile variant is associated with catecholaminergic polymorphic ventricular tachycardia |
| Q61632859 | Rarity and phenotypic heterogeneity provide challenges in the diagnosis of Andersen–Tawil syndrome: Two cases presenting with ECGs mimicking catecholaminergic polymorphic ventricular tachycardia (CPVT) |
| Q33168156 | Recurrent syncope related to catecholaminergic polymorphic ventricular tachycardia due to de novo RyR2-R2401H mutation |
| Q87630298 | Reply: Long-QT Syndrome, Brugada Syndrome, and Catecholaminergic Polymorphic Ventricular Tachycardia: A Tale of 3 Diseases : Ibutilide as a Torsade de Pointes Stress Test |
| Q88645884 | Response by Kapplinger et al to Letter Regarding Article, "Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation" |
| Q48747281 | Response to Letters Regarding Article, "Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation". |
| Q37852300 | Role of calmodulin kinase in catecholaminergic polymorphic ventricular tachycardia |
| Q33168540 | RyR2R420Q catecholaminergic polymorphic ventricular tachycardia mutation induces bradycardia by disturbing the coupled clock pacemaker mechanism |
| Q92547582 | Ryanodine receptor-bound calmodulin is essential to protect against catecholaminergic polymorphic ventricular tachycardia |
| Q44605812 | S4153R is a gain-of-function mutation in the cardiac Ca(2+) release channel ryanodine receptor associated with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. |
| Q92813180 | Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis |
| Q95935026 | Scared to death-A novel mutation in catecholaminergic polymorphic ventricular tachycardia |
| Q33157114 | Search for cardiac calcium cycling gene mutations in familial ventricular arrhythmias resembling catecholaminergic polymorphic ventricular tachycardia. |
| Q87177194 | Sensitivity and negative predictive value of treadmill exercise stress testing for the diagnosis of catecholaminergic polymorphic ventricular tachycardia |
| Q87234314 | Sensitivity and negative predictive value of treadmill exercise stress testing for the diagnosis of catecholaminergic polymorphic ventricular tachycardia. Response |
| Q41659299 | Serotonin and catecholaminergic polymorphic ventricular tachycardia : a possible therapeutic role for SSRIs? |
| Q44073503 | Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. |
| Q42215203 | Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. |
| Q38238961 | Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: risk factor and potential therapeutic target? |
| Q92974112 | Slow and steady or fast and furious? Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia |
| Q51591524 | Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography. |
| Q96585524 | Structural Abnormalities on Cardiac Magnetic Resonance Imaging in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q88317300 | Successful Treatment of Refractory Cardiac Arrest With β-Blockade and Extracorporeal Life Support in a Pediatric Patient With Catecholaminergic Polymorphic Ventricular Tachycardia: A Case Report |
| Q83447670 | Successful catheter ablation of bidirectional ventricular premature contractions triggering ventricular fibrillation in catecholaminergic polymorphic ventricular tachycardia with RyR2 mutation |
| Q28292607 | Successful treatment of catecholaminergic polymorphic ventricular tachycardia with bilateral thoracoscopic sympathectomy |
| Q37835555 | Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature |
| Q126812813 | Sudden Death by Catecholaminergic Polymorphic Ventricular Tachycardia in Children |
| Q33165068 | Sudden cardiac arrest during sex in patients with either catecholaminergic polymorphic ventricular tachycardia or long-QT syndrome: a rare but shocking experience |
| Q83976705 | Sudden cardiac death and genetic ion channelopathies: long QT, Brugada, short QT, catecholaminergic polymorphic ventricular tachycardia, and idiopathic ventricular fibrillation |
| Q91948071 | Sudden cardiac death in Long QT syndrome (LQTS), Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT) |
| Q51061333 | Sudden death due to catecholaminergic polymorphic ventricular tachycardia following negative stress-test outcome: genetics and clinical implications. |
| Q33156361 | Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation |
| Q85229026 | Sympathectomy for Patients With Catecholaminergic Polymorphic Ventricular Tachycardia: Should We Have the Nerve? |
| Q33160226 | Targeting intracellular calcium cycling in catecholaminergic polymorphic ventricular tachycardia: a theoretical investigation |
| Q36797556 | Teenage pregnancy with catecholaminergic polymorphic ventricular tachycardia and documented ICD discharges |
| Q83504637 | Ten-year follow-up of cardiac sympathectomy in a young woman with catecholaminergic polymorphic ventricular tachycardia and an implantable cardioverter defibrillator |
| Q48504966 | Tetracaine derivatives for catecholaminergic polymorphic ventricular tachycardia: new drugs for correction of diastolic Ca2+ leak? |
| Q89494185 | The Hyperpolarization-Activated Cyclic-Nucleotide-Gated Channel Blocker Ivabradine Does Not Prevent Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q28265202 | The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading [...] |
| Q33167418 | The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q28576166 | The catecholaminergic polymorphic ventricular tachycardia mutation R33Q disrupts the N-terminal structural motif that regulates reversible calsequestrin polymerization |
| Q92033310 | The challenge of implantable cardioverter-defibrillator programming and shock interpretation in treatment-refractory catecholaminergic polymorphic ventricular tachycardia |
| Q44819523 | The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry. |
| Q50070682 | The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia? |
| Q37551201 | The long QT syndrome and catecholaminergic polymorphic ventricular tachycardia |
| Q28306389 | The mechanism of catecholaminergic polymorphic ventricular tachycardia may be triggered activity due to delayed afterdepolarization |
| Q33155204 | The molecular basis of catecholaminergic polymorphic ventricular tachycardia: what are the different hypotheses regarding mechanisms? |
| Q33161368 | The phenotype of a CASQ2 mutation in a Saudi family with catecholaminergic polymorphic ventricular tachycardia |
| Q33161041 | The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands |
| Q46895569 | The role of thoracic epidural blockade in predicting responsiveness to left sympathetic denervation in patients with catecholaminergic polymorphic ventricular tachycardia |
| Q33160416 | Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments |
| Q90840280 | They Are Not Monozygotic Twins - Long QT Syndrome Type 1 (LQT1) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) |
| Q35720196 | Thoracoscopic Left Cardiac Sympathetic Denervation for a Patient with Catecholaminergic Polymorphic Ventricular Tachycardia and Recurrent Implantable Cardioverter-Defibrillator Shocks. |
| Q55365656 | Three cases of catecholaminergic polymorphic ventricular tachycardia with prolonged QT intervals including two cases of compound mutations. |
| Q84645794 | Treatment for patients with catecholaminergic polymorphic ventricular tachycardia: are we in need of randomized trials? |
| Q38014115 | Treatment of asymptomatic catecholaminergic polymorphic ventricular tachycardia |
| Q47366125 | Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs |
| Q43158949 | Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia |
| Q43888800 | Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia: reply. |
| Q46311440 | U-waves and T-wave peak to T-wave end intervals in patients with catecholaminergic polymorphic ventricular tachycardia, effects of beta-blockers |
| Q82660867 | Unmasking false epilepsy: Catecholaminergic polymorphic ventricular tachycardia |
| Q28254603 | Unraveling the mechanisms of catecholaminergic polymorphic ventricular tachycardia |
| Q45274090 | Unusual clinical presentation in a family with catecholaminergic polymorphic ventricular tachycardia due to a G14876A ryanodine receptor gene mutation |
| Q129691187 | Use of Interprofessional Simulation to Prepare for the Cardiac Emergency of Catecholaminergic Polymorphic Ventricular Tachycardia During Pregnancy |
| Q91660795 | Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy |
| Q40276777 | Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models |
| Q87809814 | Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation |
| Q115428986 | Z16b, a natural compound from Ganoderma cochlear is a novel RyR2 stabilizer preventing catecholaminergic polymorphic ventricular tachycardia |
| Q79381489 | [Arrhythmic storm induced by AICD discharge in a patient with catecholaminergic polymorphic ventricular tachycardia] |
| Q95591726 | [CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA - CASE REPORT] |
| Q72783148 | [Catecholaminergic polymorphic ventricular tachycardia in children. Differential diagnosis of epilepsy] |
| Q33159029 | [Catecholaminergic polymorphic ventricular tachycardia is a rare inherited heart disease]. |
| Q84985344 | [Catecholaminergic polymorphic ventricular tachycardia] |
| Q52407485 | [Clinical challenges in the management of catecholaminergic polymorphic ventricular tachycardia in children]. |
| Q33162225 | [Clinical features of six patients with catecholaminergic polymorphic ventricular tachycardia]. |
| Q33158598 | [Genetic of catecholaminergic polymorphic ventricular tachycardia: basic concepts]. |
| Q98732220 | [Research progress in pathogenesis and treatment of catecholaminergic polymorphic ventricular tachycardia] |
| Category:Catecholaminergic polymorphic ventricular tachycardia | wikimedia | |
| Arabic (ar / Q13955) | تسرع القلب البطيني الكاتيكولاميني متعدد الأشكال | wikipedia |
| Kateholaminska polimorfna komorska tahikardija | wikipedia | |
| Catecholaminergic polymorphic ventricular tachycardia | wikipedia | |
| Taquicardia ventricular polimórfica catecolaminérgica | wikipedia | |
| Katekoliamiiniherkkä polymorfinen kammiotakykardia | wikipedia | |
| Tachycardie ventriculaire polymorphe catécholergique | wikipedia | |
| Tachicardia ventricolare polimorfa catecolaminergica | wikipedia | |
| Wielokształtny częstoskurcz komorowy zależny od katecholamin | wikipedia | |
| Katecholaminergná polymorfná komorová tachykardia | wikipedia |
Search more.